DK0618962T3 - Thymidinphoshorylase til anvendelse ved modulering af cellulær proliferation eller kemotaxi - Google Patents

Thymidinphoshorylase til anvendelse ved modulering af cellulær proliferation eller kemotaxi

Info

Publication number
DK0618962T3
DK0618962T3 DK92922612T DK92922612T DK0618962T3 DK 0618962 T3 DK0618962 T3 DK 0618962T3 DK 92922612 T DK92922612 T DK 92922612T DK 92922612 T DK92922612 T DK 92922612T DK 0618962 T3 DK0618962 T3 DK 0618962T3
Authority
DK
Denmark
Prior art keywords
thymidine phosphorylase
cellular proliferation
chemotaxis
modulating cellular
conjugate
Prior art date
Application number
DK92922612T
Other languages
English (en)
Inventor
David James Ballance
Michael George Courtney
Christopher John Arthur Finnis
Darrell Sleep
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of DK0618962T3 publication Critical patent/DK0618962T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1077Pentosyltransferases (2.4.2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92922612T 1991-10-15 1992-10-15 Thymidinphoshorylase til anvendelse ved modulering af cellulær proliferation eller kemotaxi DK0618962T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121815A GB9121815D0 (en) 1991-10-15 1991-10-15 Medicine
PCT/GB1992/001887 WO1993008273A1 (en) 1991-10-15 1992-10-15 Thymidine phosphorylase for use in the modulation of cellular proliferation or chemotaxis

Publications (1)

Publication Number Publication Date
DK0618962T3 true DK0618962T3 (da) 2001-10-01

Family

ID=10702923

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92922612T DK0618962T3 (da) 1991-10-15 1992-10-15 Thymidinphoshorylase til anvendelse ved modulering af cellulær proliferation eller kemotaxi

Country Status (12)

Country Link
US (1) US6290953B1 (da)
EP (1) EP0618962B1 (da)
JP (1) JP3532193B2 (da)
AT (1) ATE202380T1 (da)
AU (1) AU664865B2 (da)
CA (1) CA2121358C (da)
DE (1) DE69231891T2 (da)
DK (1) DK0618962T3 (da)
ES (1) ES2160098T3 (da)
GB (1) GB9121815D0 (da)
GR (1) GR3036647T3 (da)
WO (1) WO1993008273A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2188234C2 (ru) * 2000-08-11 2002-08-27 Институт биоорганической химии им. М.М.Шемякина и Ю.А.Овчинникова РАН Способ получения рекомбинантной тимидин-фосфорилазы, рекомбинантная плазмидная днк pertpho1 и штамм escherichia coli bl21(de3)/pertpho1-продуцент тимидин-форфорилазы
EP1478328B1 (en) * 2002-01-28 2013-06-05 Keraplast Technologies Ltd. Bioactive keratin peptides
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
KR101671361B1 (ko) * 2016-08-08 2016-11-01 에스씨엠생명과학 주식회사 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178212A (en) * 1975-01-27 1979-12-11 Burroughs Wellcome Co. Stabilized thymidine phosphorylase formulation
US4347315A (en) 1980-04-25 1982-08-31 Burroughs Wellcome Co. Synthesis of ribosides using bacterial phosphorylase
EP0289229B1 (en) * 1987-04-24 1992-01-29 The Wellcome Foundation Limited Antiviral combinations
US5756686A (en) 1988-12-20 1998-05-26 Ludwig Institute For Cancer Research Peptides derived from endothelial cell growth factor
US5227302A (en) * 1988-12-20 1993-07-13 Ludwig Institute For Cancer Research DNA encoding platelet derived endothelial cell growth factor (PD-ECGF)
CA2005600A1 (en) * 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins

Also Published As

Publication number Publication date
US6290953B1 (en) 2001-09-18
JPH07501938A (ja) 1995-03-02
EP0618962A1 (en) 1994-10-12
EP0618962B1 (en) 2001-06-20
CA2121358A1 (en) 1993-04-29
ES2160098T3 (es) 2001-11-01
DE69231891T2 (de) 2002-03-28
GR3036647T3 (en) 2001-12-31
AU2872892A (en) 1993-05-21
GB9121815D0 (en) 1991-11-27
AU664865B2 (en) 1995-12-07
DE69231891D1 (de) 2001-07-26
JP3532193B2 (ja) 2004-05-31
WO1993008273A1 (en) 1993-04-29
ATE202380T1 (de) 2001-07-15
CA2121358C (en) 2003-12-30

Similar Documents

Publication Publication Date Title
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
NO20004027L (no) Fluorinerte ionomerer og deres anvendelser
BR9610133A (pt) Vetor recombinante, organismo hospedeiro gram-positivo, processos para engenheirar um organismo hospedeiro gram-positivo, para mostrar a proteìna ou polipeptìdeo desejado em sua superfìcie, para imobilizar organismo hospedeiro gram-positivo e para triar uma coleção de substâncias, vacina, composição e usos de organismos hospedeiro e da composição.
DK1061805T3 (da) Regulering af den endogene genekspression i celler ved anvendelse af zinkfingerproteiner
TR199700610A3 (tr) Düsük molekül agirlikli çözünür, tümör nekroz faktörü tip-I ve tip-II proteinleri.
DK463586A (da) Fsh
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
PT921812E (pt) Preparacoes de insulina contendo um halogenuro
ES2150233T3 (es) Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma.
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
BR9006855A (pt) Proteina de atividade urato oxidase,gene recombinante que a codifica,vetor de expressao,microorganismos e celulas transformadas
BR9808327A (pt) Aminossulfoniluréias, herbicidas, composição herbicida, e, processos para a preparação das aminossulfoniluréias e para controlar ervas daninhas em áreas cultivadas
AU8040898A (en) Type-1 ribosome-inactivating protein
HU9300397D0 (en) Method for modifying tropism of micor-organisms to cells, tissues and host organisms recombinant micro-organisms obtained by this way and their application in human and veterinary medicine
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
ATE183775T1 (de) Cysteinfreie il-6 mutanten
DK0618962T3 (da) Thymidinphoshorylase til anvendelse ved modulering af cellulær proliferation eller kemotaxi
DK381189A (da) N-2,3-butadienyl-tri- og -tetraaminoalkanderivater og deres anvendelse
ES2150021T3 (es) Derivados de acidos piridin- y pirazin-dicarboxilicos como reguladores de la proliferacion celular.
EP0154566A3 (en) Viral enhancer dna segments
BR0014634A (pt) Proteìnas dp de trigo e uso das mesmas
BR9814425A (pt) Aço inoxidável austenìtico incluindo colúmbio
DE69605201D1 (de) Erhaltung von schutzflächen auf kohlenstoff-kathoden in aluminium - elektrolyseofen